Skip to main content
SpringerLink
Log in

Underutilisation of ACE Inhibitors in Patients with Congestive Heart Failure

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Congestive heart failure (CHF) is associated with substantial morbidity and mortality, and is the only major cardiovascular disease increasing in prevalence. Despite abundant evidence to support their efficacy and cost-effectiveness, angiotensin-converting enzyme (ACE) inhibitors are sub-optimally used in patients with CHF. This paper reviews the evidence for the sub-optimal use of ACE inhibitors in patients with CHF, the factors contributing to this, and its implications for health systems.

A systematic review of all articles assessing practice patterns (specifically the use of ACE inhibitors in CHF) identified by MEDLINE, search of bibliographies, and contact with content experts was undertaken.

37 studies have documented the use of ACE inhibitors in patients with CHF. Studies assessing use among all patients with CHF document 33% to 67% (median 51%) of all patients discharged from hospital and 10% to 36% (median 26%) of community dwelling patients were prescribed ACE inhibitors. Rates of ACE inhibitor use range from 43% to 90% (median of 71%) amongst those discharged from hospital having known systolic dysfunction, and from 67% to 95% (median of 86%) for those monitored in specialty clinics. Moreover, the dosages used in the ‘real world’ are substantially lower than those proven efficacious in randomised, controlled trials, with evaluations reporting only a minority of patients achieving target doses and/or an overall mean dose achieved to be less than one-half of the target dose. Factors predicting the use and optimal dose administration of ACE inhibitors are identified, and include variables relating to the setting (previous hospitalisation, specialty clinic follow-up), the physician (cardiology specialty versus family practitioner or general internist, board certification), the patient (increased severity of symptoms, male, younger), and the drug (lower frequency of administration).

In light of the substantial evidence for reductions in morbidity and mortality, clearly, the prescription of ACE inhibitors is sub-optimal. Wide variability in ACE inhibitor use is noted, with higher rates consistently reported among patients having systolic dysfunction confirmed by an objective assessment —an apparent minority of the those having CHF. Optimisation of the prescription of proven efficacious therapies has the potential to confer a substantial reduction in the total cost of care for patients with CHF by reducing hospitalisations and lengths of hospital stays. It is likely that only multifaceted programs targeted toward the population at large will yield benefits to the healthcare system, given the widespread nature of the sub-optimal prescription of therapies proven effective in the management of patients with CHF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. American Society of Health-System Pharmacists. ASHP Therapeutic Guidelines on angiotensin-converting-enzyme inhibitors in patients with left ventricular dysfunction. Am J Health Syst Pharm 1997; 54: 299–313

    Google Scholar 

  2. McKee P, Castelli W, McNamara P, et al. The natural history of congestive heart failure: the Framingham Study. N Engl J Med 1971; 285: 1441–6

    Article  PubMed  CAS  Google Scholar 

  3. Ackman M, Teo K, Montague T. Clinical and epidemiological challenges of congestive heart failure. Prairie Med J 1995; 65: 109–12

    Google Scholar 

  4. Brophy JM. Epidemiology of congestive heart failure: Canadian data from 1970 to 1989. Can J Cardiol 1992; 8: 495–8

    PubMed  CAS  Google Scholar 

  5. Rajfer SI. Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol 1993; 22 Suppl. A: 198A–200A

    Article  PubMed  CAS  Google Scholar 

  6. The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hopitalized medicare patients. Arch Intern Med 1997; 157: 1103–8

    Article  Google Scholar 

  7. Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health 1997; 87: 643–8

    Article  PubMed  CAS  Google Scholar 

  8. Johnstone DE, Abdulla A, Arnold JMO, et al. Diagnosis and management of heart failure: Canadian Cardiovascular Society consensus conference. Can J Cardiol 1994; 10: 613–31

    PubMed  CAS  Google Scholar 

  9. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991; 325: 303–10

    Article  PubMed  CAS  Google Scholar 

  10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 429–35

    Google Scholar 

  11. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91

    Article  Google Scholar 

  12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302

    Article  Google Scholar 

  13. Butler JR. Fletcher PJ. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Aust N Z J Med 1996; 26: 89–95

    CAS  Google Scholar 

  14. Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial. J Cardiac Failure 1995; 1: 371–80

    Article  CAS  Google Scholar 

  15. McMurray J, McDonagh T, Morrison CE, et al. Trends in hospitalisations for chronic heart failure in Scotland. Eur Heart J 1993; 14: 1158–62

    Article  PubMed  CAS  Google Scholar 

  16. Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143–9

    Article  PubMed  CAS  Google Scholar 

  17. van Hout BA, Wielink G, Bonsel GJ, et al. Effects of ACE inhibitors on heart failure in the Netherlands: a pharmacoeconomic model. PharmacoEconomics 1993; 3: 387–97

    Article  PubMed  Google Scholar 

  18. European Society of Cardiology. Treatment of heart failure: report of the task force of the working group on heart failure of the European Society of Cardiology. Eur Heart J 1997; 18: 736–53

    Article  Google Scholar 

  19. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. Rockville (MD): Agency for Health Care Policy and Research; 1994. Clinical practice guideline no. 11, AHCPR Publication no. 94-0612; 1994: 1–122

    Google Scholar 

  20. The steering committee and membership of the advisory council to improve outcomes nationwide in heart failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83(2A): 2A–8A

    Google Scholar 

  21. Williams JF, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiololgy/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995; 26: 1376–98

    Article  Google Scholar 

  22. Pacher R, Globits S, Bergler-Klein J, et al. Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. Eur Heart J 1993; 14: 273–8

    Article  PubMed  CAS  Google Scholar 

  23. Riegger GAJ. Effects of quniapril on exercise tolerance in patients with mild to moderate heart failure. Eur Heart J 1991; 12: 705–11

    Article  PubMed  CAS  Google Scholar 

  24. Van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998; 32: 1811–8

    Article  PubMed  Google Scholar 

  25. Pacher M, Poole-Wilson PA, Armstrong PQ, et al. Comparative effects of low versus high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312–8

    Article  Google Scholar 

  26. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19: 481–9

    Article  Google Scholar 

  27. Ackman ML, Teo KK, Montague TJ. Impact of regionally developed practice guidelines on management of congestive heart failure [abstract]. Circulation 1996; 94 Suppl. I: I506

    Google Scholar 

  28. Bart BA, Gattis WA, Diem SJ, et al. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997; 79: 1118–20

    Article  PubMed  CAS  Google Scholar 

  29. Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993; 22 Suppl. A: 14A–19A

    Article  PubMed  CAS  Google Scholar 

  30. Chin MH, Wang JC, Zhang JX, et al. Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure: effect of physician specialty and patient characteristics. J Gen Intern Med 1997; 12: 563–6

    Article  PubMed  CAS  Google Scholar 

  31. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation of treatment of patients with heart failure. Br Heart J 1994; 71: 584–7

    Article  PubMed  CAS  Google Scholar 

  32. Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex, and medical therapy. Arch Intern Med 1996; 156: 1669–73

    Article  Google Scholar 

  33. Croft JB, Giles WH, Rowgner RH, et al. Pharmacologic management of heart failure among older adults by office-based physicians in the United States. J Fam Pract 1997; 44: 382–90

    PubMed  CAS  Google Scholar 

  34. Ferreira A, Bettencourt P, Cortez M, et al. Angiotensin-converting enzyme inhibitors in heart failure: physicians’ prescribing behaviour. J Cardiac Failure 1997; 3: 295–302

    Article  CAS  Google Scholar 

  35. Ghali JK, Giles T, Gonzles M, et al. Patterns of physician use of angiotensin converting enxyme inhibitors in the inpatient treatment of congestive heart failure. J La State Med Soc 1997; 149: 474–84

    PubMed  CAS  Google Scholar 

  36. Hillis GS, Al-Mohammad A, Wood M, et al. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart 1996; 76: 427–9

    Article  PubMed  CAS  Google Scholar 

  37. Houghton AR, Cowley AJ. Managing heart failure in a specialist clinic. J Royal Col Phys London 1997; 31: 276–9

    CAS  Google Scholar 

  38. Kornowski R, Zeeli D, Averbuch M, et al. Intensive home-care surveillance prevents hospitalization and improves morbidity rates among elderly patients with severe congestive heart failure. Am Heart J 1995; 129: 762–6

    Article  PubMed  CAS  Google Scholar 

  39. Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of appropriate use of antiotensin-converting enzyme inhbitors after acute myocardial infarction in persons ≥65 years of age. Am J Cardiol 1997; 79: 581–6

    Article  PubMed  CAS  Google Scholar 

  40. Krumholz HM, Wany Y, Parent EM, et al. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med 1997; 157: 2242–7

    Article  PubMed  CAS  Google Scholar 

  41. Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitors underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998; 82: 465–9

    Article  PubMed  CAS  Google Scholar 

  42. Mair FS, Crowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 1996; 46: 77–9

    PubMed  CAS  Google Scholar 

  43. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999; 138: 87–94

    Article  PubMed  CAS  Google Scholar 

  44. McDermott MM, Feinglass J, Lee P, et al. Heart fialure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J 1997; 134: 901–9

    Article  PubMed  CAS  Google Scholar 

  45. McDermott MM, Feinglass J, Sy J, et al. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. Am J Med 1995; 99: 629–35

    Article  PubMed  CAS  Google Scholar 

  46. McDermott MM, Lee P, Hehta S, et al. Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure. Clin Cardiol 1998; 21: 261–8

    Article  PubMed  CAS  Google Scholar 

  47. Missouris CG, MacGregor GA. The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice. Postgrad Med J 1997; 73: 409–11

    Article  PubMed  CAS  Google Scholar 

  48. Parameshwar J, Poole-Wilson PA, Sutton GC. Heart failure in a district general hospital. J Royal Coll Phys London 1992; 26: 139–42

    CAS  Google Scholar 

  49. Parameshwar J, Shackell MM, Richardson A, et al. Prevalence of heart failure in three general practices in north west London. Br J Gen Pract 1992; 42: 287–9

    PubMed  CAS  Google Scholar 

  50. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol 1998; 21: 103–8

    Article  PubMed  CAS  Google Scholar 

  51. Philbin EF, Andreou C, Rocco TA, et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996; 77: 832–8

    Article  PubMed  CAS  Google Scholar 

  52. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997; 30: 733–8

    Article  PubMed  CAS  Google Scholar 

  53. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–5

    Article  PubMed  CAS  Google Scholar 

  54. Rich MW, Brooks K, Luther P. Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990–1995. Am Heart J 1998; 135: 367–72

    Article  PubMed  CAS  Google Scholar 

  55. Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol 1999; 33: 164–70

    Article  PubMed  CAS  Google Scholar 

  56. Shah NB, Der E, Ruggerio C, et al. Prevention of hospitalizations for heart failure with an interactive home monitoring program. Am Heart J 1998; 135: 373–8

    Article  PubMed  CAS  Google Scholar 

  57. Smith LE, Fabri SA, Pai R, et al. Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. Clin Cardiol 1997; 20: 949–54

    Article  PubMed  CAS  Google Scholar 

  58. Smith NL, Psaty BM, Pitt B, et al. Temporal patterns in the medical treatment of congestive heart failure with angioensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998; 158: 1074–80

    Article  PubMed  CAS  Google Scholar 

  59. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhbitor use in congestive heart failure. Arch Intern Med 1997; 157: 2460–4

    Article  PubMed  CAS  Google Scholar 

  60. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995; 26: 1417–23

    Article  PubMed  CAS  Google Scholar 

  61. Tsuyuki RT, Teo KK, Ackman ML, et al. Temporal changes in medication use in patients with congestive heart failure: 1992/93 vs. 1994/95. Can J Cardiol 1998; 14 Suppl. F: 130F

    Google Scholar 

  62. Fonarow GC, Stevenson LW, Waiden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997; 30: 725–32

    Article  PubMed  CAS  Google Scholar 

  63. Gattis WA, Larsen RL, Hasselblad V, et al. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? Am Heart J 1998; 136: 43–8

    Article  PubMed  CAS  Google Scholar 

  64. Manyari DE, Gutierrez R, Belenkie I, et al. Dose of angiotensin converting enzyme inhibitors in patients with heart failure: understanding the gap between clinical trials and clinical practice. Eur Heart J 1999: 499

  65. West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 1997; 79: 58–63

    Article  PubMed  CAS  Google Scholar 

  66. Erhardt L, Cline C. Heart failure clinics: a possible means of improving care. Heart 1998; 80: 428–9

    PubMed  CAS  Google Scholar 

  67. Stromberg A. Heart failure clinics. Heart 1998; 80: 426–7

    PubMed  CAS  Google Scholar 

  68. McMurray JJV. Failure to practice evidence-based medicine: why do phsyicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998; 19 Suppl. L: L15–L21

    PubMed  Google Scholar 

  69. Edep ME, Shah NB, Tateo IM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997; 30: 518–26

    Article  PubMed  CAS  Google Scholar 

  70. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997; 59: 7–10

    Article  PubMed  CAS  Google Scholar 

  71. Chin MH, Fridemann PD, Cassel CK, et al. Differences in generalist and specialist physicians’ knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med 1997; 12: 523–30

    Article  PubMed  CAS  Google Scholar 

  72. Shah N, Edep M, Massie M. Differences between cardiologists and heart failure specialists in the management of congestive heart failure. Circulation 1995; 92 Suppl. 1: I–666

    Google Scholar 

  73. Martens KH, Dempsey-Mellor S. A study of the relationship between home care services and hospital readmission of patients with congestive heart failure. Home Healthc Nurse 1997; 15: 123–9

    Article  PubMed  CAS  Google Scholar 

  74. Stewart S, Vandenbroek AJ, Pearson S, et al. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999; 159: 257–61

    Article  PubMed  CAS  Google Scholar 

  75. Rich MW, Vinson JM, Sperry JC, et al. Prevention of readmission in elderly patients with congestive heart failure: results of a prospective, randomized pilot study. J Gen Intern Med 1993; 8: 585–90

    Article  PubMed  CAS  Google Scholar 

  76. McAlister FA, Lawson FME, Teo KK, et al. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001; 110: 378–84

    Article  PubMed  CAS  Google Scholar 

  77. O’Reilly M. Is internet-based disease management on the way? CMAJ 1999; 160: 1039

    Google Scholar 

  78. McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics 1996; 9: 188–97

    Article  PubMed  CAS  Google Scholar 

  79. Simons WR, Haim M, Rizzo J, et al. Effect of improved disease management strategies on hospital length of stay in the treatment of congestive heart failure. Clin Ther 1996; 18: 726–46

    Article  PubMed  CAS  Google Scholar 

  80. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Econ 1993; 6: 91–8

    Google Scholar 

  81. O’Connell JB, Bristow M. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1993; 13 Suppl.: S107–S12

    Google Scholar 

Download references

Acknowledgements

Drs Bungard, McAlister and Johnson are supported by the Alberta Heritage Foundation for Medical Research. No funding was received to assist in the preparation of this manuscript and there are no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

    Tammy J. Bungard &  Ross T. Tsuyuki

  2. Division of General Internal Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

    Finlay A. McAlister

  3. Department of Public Health Sciences, Faculty of Medicine and Dentistry, University of Alberta and Institute of Health Economics, Edmonton, Alberta, Canada

    Jeffrey A. Johnson

Authors
  1. Tammy J. Bungard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Finlay A. McAlister
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey A. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ross T. Tsuyuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ross T. Tsuyuki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bungard, T.J., McAlister, F.A., Johnson, J.A. et al. Underutilisation of ACE Inhibitors in Patients with Congestive Heart Failure. Drugs 61, 2021–2033 (2001). https://doi.org/10.2165/00003495-200161140-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161140-00002

Keywords

Search

Navigation